While HFA-ICOS risk predicts cardiac events in patients with breast cancer receiving anthracycline and/or anti-HER2 therapies, future studies should evaluate whether imaging surveillance in higher risk individuals mitigates this risk. The gene discussed is ERBB2; the disease is breast cancer.